Cancer
Malignant Nasopharyngeal Neoplasm
CI-CAN-00005902Explore in graph →
Top-level261 active trials1 approved drugs
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005902Explore in graph →
Clinical trials
771 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (43)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05020067 | Impact on Xerostomia for Nasopharyngeal Carcinoma Patients Treated With or Without Superficial Parotid Lobe-sparing Intensity-modulated Radiotherapy | completed | Phase 2 | 90 | Sun Yat-sen UniversityOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT05020925 | SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 1 / Phase 2 | 30 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 25, 2021 |
| clinicaltrials |
| NCT03668730 | Reduced-dose Radiotherapy for Low-risk Stage III Patients With Nasopharyngeal Carcinoma | unknown | Phase 2 | 215 | Sun Yat-sen UniversityOTHER | 1 | Aug 24, 2021 | clinicaltrials |
| NCT04992988 | Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial | unknown | Phase 2 | 40 | Cancer Hospital of Guangxi Medical UniversityOTHER | 1 | Aug 20, 2021 | clinicaltrials |
| NCT01094405 | Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy | completed | Phase 2 | 25 | Chinese University of Hong KongOTHER | 1 | Jul 28, 2021 | clinicaltrials |
| NCT04955886 | Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 14 | Fujian Cancer HospitalOTHER_GOV | 1 | Jul 9, 2021 | clinicaltrials |
| NCT03904225 | Tegio Consolidation Therapy for NPC Patients With High Risk of Metastasis | unknown | Phase 2 | 220 | Zhejiang Cancer HospitalOTHER | 1 | Jun 23, 2021 | clinicaltrials |
| NCT04917770 | The Efficacy and Safety of Sintilimab in Combination With Multimodal Radiotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 28 | West China HospitalOTHER | 0 | Jun 8, 2021 | clinicaltrials |
| NCT04890522 | An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC | not yet recruiting | Phase 2 / Phase 3 | 622 | Sun Yat-sen UniversityOTHER | 1 | May 18, 2021 | clinicaltrials |
| NCT03390738 | Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy | withdrawn | Phase 2 | 0 | The University of Hong KongOTHER | 0 | May 3, 2021 | clinicaltrials |
| NCT00896181 | Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC) | completed | Phase 2 | 26 | Stanford UniversityOTHER | 1 | Apr 6, 2021 | clinicaltrials |
| NCT04769076 | The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal Carcinoma | unknown | Phase 2 | 40 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Feb 25, 2021 | clinicaltrials |
| NCT03668366 | S-1 Combined With IMRT Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma | completed | Phase 2 | 133 | Fudan UniversityOTHER | 1 | Feb 11, 2021 | clinicaltrials |
| NCT02636231 | Endostar for Locally Recurrent Nasopharyngeal Carcinoma | unknown | Phase 2 | 96 | Sun Yat-sen UniversityOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT03908372 | Optimized Treatment Strategies for Early and Medium Stage Nasopharyngeal Carcinoma | unknown | Phase 2 / Phase 3 | 120 | Chinese Academy of Medical SciencesOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT03915132 | Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma | unknown | Phase 2 | 47 | Chinese Academy of Medical SciencesOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT04627961 | A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 33 | National University Hospital, SingaporeOTHER | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04231864 | Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer | withdrawn | Phase 2 | 0 | Alain AlgaziOTHER | 0 | Oct 26, 2020 | clinicaltrials |
| NCT03129412 | Oligo-metastases NPC Patients Received Radiation for Primary Tumors and Treatments for Metastatic Lesions | unknown | Phase 2 | 64 | Zhejiang Cancer HospitalOTHER | 1 | Sep 17, 2020 | clinicaltrials |
| NCT04553510 | Treatment of Bevacizumab Followed by Steroid in RN | unknown | Phase 2 | 86 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 17, 2020 | clinicaltrials |
| NCT04547088 | Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 27 | Sun Yat-sen UniversityOTHER | 1 | Sep 14, 2020 | clinicaltrials |
| NCT04548271 | Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Sep 14, 2020 | clinicaltrials |
| NCT04534855 | A Phase II Clinical Study of Treprilimab in the Treatment of Recurrent Nasopharyngeal Carcinoma After Re-irradiation | unknown | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 0 | Sep 1, 2020 | clinicaltrials |
| NCT03648697 | EBV-TCR-T（YT-E001）for Patients With EBV-positive Recurrent or Metastatic NPC | unknown | Phase 2 | 20 | Fujian Cancer HospitalOTHER_GOV | 1 | Aug 11, 2020 | clinicaltrials |
| NCT04476641 | A Study of DC-CIK Immunotherapy in the Treatment of Solid Tumors(DC-CIK) | unknown | Phase 2 | 686 | Sun Yat-sen UniversityOTHER | 1 | Jul 20, 2020 | clinicaltrials |
| NCT01187238 | The Value of Concurrent Chemoradiotherapy for Stage II Nasopharyngeal Carcinoma | completed | Phase 2 | 84 | Chinese Academy of Medical SciencesOTHER | 1 | Jul 16, 2020 | clinicaltrials |
| NCT04447326 | Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy for Nasopharyngeal Carcinoma | unknown | Phase 2 | 106 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 0 | Jun 25, 2020 | clinicaltrials |
| NCT04447612 | Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma | unknown | Phase 2 | 118 | The University of Hong KongOTHER | 1 | Jun 25, 2020 | clinicaltrials |
| NCT04421469 | Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPC | unknown | Phase 2 | 39 | Fujian Cancer HospitalOTHER_GOV | 1 | Jun 9, 2020 | clinicaltrials |
| NCT00367718 | Trial of VELCADE in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma | withdrawn | Phase 2 | 0 | Johns Hopkins UniversityOTHER | 2 | May 18, 2020 | clinicaltrials |
| NCT04319471 | Sufficient Chemotherapy Combine With Maintenance Chemotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 70 | Fujian Cancer HospitalOTHER_GOV | 1 | Mar 24, 2020 | clinicaltrials |
| NCT01469429 | Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. | completed | Phase 1 / Phase 2 | 70 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 20, 2020 | clinicaltrials |
| NCT02569788 | Trail Evaluating Carbon Ion Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma | terminated | Phase 1 / Phase 2 | 9 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT02801487 | Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma | terminated | Phase 1 / Phase 2 | 6 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT03923842 | Denosumab In Ebv Nasopharyngeal Carcinoma As A Model For RankMediated Immunologic Modulation Of Virus-Related Tumours(Dern) | unknown | Phase 2 | 45 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT04220528 | Radical Radiotherapy and Chemotherapy Combined With Maintenance Chemotherapy in the Treatment of Stage N3 NPC | unknown | Phase 2 | 129 | Fujian Cancer HospitalOTHER_GOV | 1 | Jan 7, 2020 | clinicaltrials |
| NCT03389295 | Reduced Target Delineation and Radiation Doses Chemoradiotherapy for Patients With Locoregionally Advanced Nasopharyngeal Carcinoma | completed | Phase 2 | 118 | Xiayun He, MDOTHER | 1 | Dec 16, 2019 | clinicaltrials |
| NCT01230476 | Induction and Concurrent Chemoradiotherapy With Cetuximab for Patients With Locally Advanced Nasopharyngeal Carcinoma | terminated | Phase 2 | 3 | University of MalayaOTHER | 1 | Oct 7, 2019 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT02794077 | Cyclophosphamide for Nasopharyngeal Carcinoma | completed | Phase 2 | 56 | The University of Hong KongOTHER | 0 | Oct 2, 2019 | clinicaltrials |
| NCT02339558 | Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 3 | Sep 13, 2019 | clinicaltrials |
| NCT03007836 | High-activity Natural Killer Immunotherapy for Small Metastases of Nasopharyngeal Cancer | completed | Phase 1 / Phase 2 | 20 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02789189 | Nedaplatin Combined With Gemcitabine in the Treatment of Recurrent and/or Metastatic Nasopharyngeal Carcinoma : a Single Arm and Phase Ⅱ Clinical Trail | terminated | Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 0 | Sep 6, 2019 | clinicaltrials |
| NCT03020329 | Induction Chemotherapy in Young Patients With Locoregionally Advanced Nasopharyngeal Carcinoma | unknown | Phase 2 | 37 | Sun Yat-sen UniversityOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT01309633 | Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC) | completed | Phase 2 | 80 | National University Hospital, SingaporeOTHER | 1 | Jul 22, 2019 | clinicaltrials |
| NCT04015661 | Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Patients With LA-NPC | unknown | Phase 2 | 92 | Fuzhou General HospitalOTHER | 1 | Jul 11, 2019 | clinicaltrials |
| NCT02123511 | Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy | completed | Phase 2 | 34 | Mayo ClinicOTHER | 1 | Apr 30, 2019 | clinicaltrials |
| NCT03932266 | Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal Carcinoma | unknown | Phase 2 | 73 | Jiangsu Cancer Institute & HospitalOTHER | 0 | Apr 30, 2019 | clinicaltrials |
| NCT02706691 | BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer | terminated | Phase 2 | 1 | University of ChicagoOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT03890185 | Docetaxal & Cisplatin vs LDFRT + Docetaxal & Cisplatin in Locally Advanced NPC | unknown | Phase 2 | 108 | King Faisal Specialist Hospital & Research CenterOTHER | 0 | Mar 26, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Aug 25, 2021source: clinicaltrials